The U.S. Food and Drug Administration issued in June 2023 draft guidelines for clinical investigations of psychedelic drugs. CERL Executive Board Member Brig. Gen. (Ret.) Stephen N. Xenakis, who was recently appointed to lead the American Psychedelic Practitioners Association (APPA), spoke with Behavioral Health Business about this development.

Brig. Gen. Xenakis is an adult, child, and adolescent psychiatrist with many years of clinical, academic, and management experience. His recent work focuses on the promise of psychedelic therapies, particularly as treatment for combat veterans. He is an advisor for Physicians for Human Rights and the Center for Victims of Torture. He is also an Adjust Professor at Uniformed Services University of the Health Sciences. Read his bio here.